Kura Oncology, Inc. (KURA) Earnings
Kura Oncology, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.94. KURA has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise -166.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.88 | $-0.83 | +5.7% | $18M | -29.7% |
| Mar 5, 2026 | $-0.64 | $-0.92 | -44.0% | $17M | +17.7% |
| Aug 7, 2025 | $0.15 | $-0.75 | -600.0% | $15M | -76.5% |
| May 1, 2025 | $-0.51 | $-0.66 | -29.4% | $14M | -78.8% |
| Feb 26, 2025 | $-0.65 | $-0.22 | +66.2% | $54M | -7.0% |
| Nov 7, 2024 | $-0.64 | $-0.63 | +1.6% | — | — |
| May 2, 2024 | $-0.56 | $-0.59 | -5.4% | — | — |
| Feb 27, 2024 | $-0.56 | $-0.55 | +1.8% | $1M | — |
| Nov 2, 2023 | $-0.56 | $-0.50 | +10.7% | — | — |
| Aug 3, 2023 | $-0.57 | $-0.53 | +7.0% | — | — |
| Feb 23, 2023 | $-0.58 | $-0.49 | +15.5% | — | — |
| Nov 3, 2022 | $-0.57 | $-0.53 | +7.0% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 12, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Commercial Launch of ComSifty - ComSifty generated $5.8 million in net product revenue in its first full commercial quarter, exceeding internal expectations, with 85 new patient starts, ~160 total one-month prescriptions, and treatment across 60 activated treatment centers. - Early commercial trends are positive: 40% of new patients are prescribed ComSifty off-label in combination with other standard AML therapies, physicians are switching patients from competing menin inhibitors to ComSifty, and repeat prescriptions confirm growing clinician confidence. - Payer access is strong: ComSifty has secured parity or better coverage for more than 93% of covered lives with no label restrictions, and over 10 plans covering 12 million lives have assigned it favorable formulary positioning. ### Clinical Development Pipeline (AML) - The strategy for ComSifty (zipdomenib) is to establish it as a broadly combinable backbone therapy across the entire AML treatment continuum, with multiple data readouts expected in 2026. - The frontline phase 3 COMET-017 trial, which uses a streamlined one-stop-shop design enabling two parallel trials per activated site, is progressing ahead of enrollment projections with strong global site participation across the U.S., Europe, and Asia. - 2026 planned clinical data readouts include: updated 7+3 combination data for newly diagnosed AML at EHA (June), publication of venetoclax + azacitidine combination data for relapsed/refractory AML, and initial FLT3 inhibitor combination data in H2 2026. ### Pipeline Expansion Beyond AML - Darlifarnib, a farnesyl transferase inhibitor developed to overcome resistance to targeted cancer therapies, is advancing in combination trials. Preliminary combination data with adagrasib in KRAS G12C mutated solid tumors will be presented at ASCO, with a full Phase 1a data update planned later in 2026. - Early combination data for darlifarnib plus cabozantinib in pre-treated clear cell renal cell carcinoma has confirmed proof of mechanism, and Phase 1b enrollment is ongoing. A trial of zipdomenib plus imatinib in gastrointestinal stromal tumors (GIST) is also progressing well. ### Financial Position - As of March 31, 2026, Cura holds sufficient cash, cash equivalents, and short-term investments to fund its core AML program through the expected 2028 top-line readout of COMET-017, when combined with anticipated future collaboration payments.
Guidance
- Collaboration revenue guidance for 2026-2028 is maintained at: $45 million to $55 million for 2026, $90 million to $110 million for 2027, and $90 million to $110 million for 2028. - Initial top-line data from the COMET-017 phase 3 trial remains expected in 2028; management notes enrollment is ahead of schedule but has not formally pulled forward the readout timeline at this time. - Management reaffirms its expectation of steady quarter-over-quarter revenue growth for ComSifty and targets gaining leading market share (greater than 50%) in the relapsed/refractory NPM1 mutant AML market, which is estimated at $350 million to $400 million in total size.
Segment performance
Cura Oncology has two main revenue segments in Q1 2026: 1. Net product revenue (from ComSifty, the company's first commercial menin inhibitor): $5.8 million (100% of product revenue, 31.7% of total Q1 2026 revenue). 2. Collaboration revenue (from the Kiowa-Carran partnership): $12.5 million (68.3% of total Q1 2026 revenue), down from $14.1 million in Q1 2025. Total operating expenses for Q1 2026 were $96.9 million, consisting of: - Research and development expenses: $65.3 million, up from $56 million in Q1 2025, driven by increased activity for ComSifty and the COMET 017 phase 3 trial. - Selling, general, and administrative expenses: $31.6 million, up from $22.8 million in Q1 2025, driven by commercial launch activities for ComSifty. Net loss for Q1 2026 was $73.3 million, wider than the $57.4 million net loss in Q1 2025.
Risks & headwinds
- All forward-looking statements related to clinical trial outcomes, market share gains, and revenue growth are subject to inherent risks and uncertainties that could cause actual results to differ materially from expectations, as detailed in Cura's SEC filings. - Early commercial and clinical trends (including treatment duration, combination use, and switching rates) are based on a small patient population from one quarter of data, and long-term trends may differ from early observations. - There is no guarantee that positive off-label physician use of ComSifty in combination will lead to formal approval or NCCN guideline inclusion for combination indications. - ComSifty is second to market in the menin inhibitor class, and competition for market share could limit future growth.
Analyst Q&A
Q: Can you share your observations of the 40% off-label combination use of ComSifty across practice settings, and how do you expect adoption to evolve as more combination data is released? /
A: The spontaneous combination use we are seeing is supported by early clinical data that demonstrates ComSifty's safety profile supports combination therapy. We expect the upcoming publication of venetoclax + azacitidine combination data will further increase use, and we plan to submit this data for NCCN guideline consideration. ComSifty's ability to combine safely with FLT3 inhibitors gives it a unique advantage in the large subset of NPM1-mutant AML patients that also have FLT3 mutations.
Q: The COMET-017 frontline phase 3 trial is enrolling ahead of schedule. Can you share additional details, and does this change your timeline for top-line readouts? /
A: We have seen extremely strong excitement and rapid enrollment across all global regions (U.S., Europe, Asia), which matches the faster-than-projected enrollment we saw in our earlier phase 1 COMET-007 trial. We have not changed our guidance for the initial 2028 top-line readout, though we may tighten the timeline as we get closer to the readout. The trial's innovative design that combines two phase 3 trials in one protocol significantly accelerates enrollment, and we are significantly ahead of competing programs in the frontline setting.
Q: Can you comment on why physicians are switching patients from competing menin inhibitors to ComSifty, and what this signals about market share? /
A: It is too early to share granular patient-level details, but at a high level, switching is driven by physicians choosing ComSifty for its differentiated profile including stronger efficacy, more manageable safety, and simpler once-daily dosing. The most important signal is that we captured 40% of all new NPM1-mutant patient starts in our first full quarter as a second-to-market entrant, which is very strong early momentum. We expect our new patient share to continue growing and we target a leading (over 50%) market share in this indication.
Q: How much of the $5.8 million Q1 revenue came from inventory stocking, and can you comment on how combination use might impact treatment duration? /
A: There is no meaningful inventory stocking impacting the Q1 revenue number. It is too early to give a definitive view on how combination use impacts treatment duration after only one full quarter of commercial data, but our baseline expectation is that patients on combination therapy will likely have longer treatment durations than patients on monotherapy. We need several more quarters of data to track this trend accurately, and we reaffirm our current $350-$400 million total market estimate for this indication.